Alzheimer’s disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, …

The heterogeneity of neurodegenerative diseases is a key confound to disease understanding
and treatment development, as study cohorts typically include multiple phenotypes on …

See Stankoff and Louapre (doi: 10.1093/brain/awy114 ) for a scientific commentary on this
article. Grey matter atrophy is present from the earliest stages of multiple sclerosis, but its …

We demonstrate the use of a probabilistic generative model to explore the biomarker changes
occurring as Alzheimer’s disease develops and progresses. We enhanced the recently …

Multiple sclerosis (MS) can be divided into four phenotypes based on clinical evolution. The
pathophysiological boundaries of these phenotypes are unclear, limiting treatment …

See Li and Donohue (doi: 10.1093/brain/awy089 ) for a scientific commentary on this article.
Dominantly-inherited Alzheimer’s disease is widely hoped to hold the key to developing …

The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge
compares the performance of algorithms at predicting future evolution of individuals at risk of …

Dementia is one of the most debilitating aspects of Parkinson’s disease. There are no
validated biomarkers that can track Parkinson’s disease progression, nor accurately identify …

Posterior cortical atrophy is a clinico-radiological syndrome characterized by progressive
decline in visual processing and atrophy of posterior brain regions. With the majority of cases …

Rationale: The decades-long progression of chronic obstructive pulmonary disease (COPD)
renders identifying different trajectories of disease progression challenging. Objectives: To …